Day: May 2, 2026

Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the...

error: Content is protected !!